GoodRx Holdings, Inc. (NASDAQ:GDRX) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET

Company Participants

Aubrey Reynolds – Director of Investor Relations
Scott Wagner – Interim Chief Executive Officer
Karsten Voermann – Chief Financial Officer

Conference Call Participants

Stephanie Davis – Barclays
Charles Rhyee – TD Cowen
Lisa Gill – J.P. Morgan
Scott Schoenhaus – KeyBanc
Stan Berenshteyn – Wells Fargo Securities
Sean Dodge – RBC Capital Markets
Jailendra Singh – Truist Securities
Allen Lutz – Bank of America
Daniel Grosslight – Citi
George Hill – Deutsche Bank
Eric Sheridan – Goldman Sachs
Dan Clark – Leerink

Operator

Hello, ladies and gentlemen, and thank you for standing by and welcome to the GoodRx Third Quarter 2024 Earnings Call. As a reminder, today’s conference call is being recorded.

I would now like to introduce your host for today’s call, Aubrey Reynolds, Director of Investor Relations. Ms. Reynolds, you may begin.

Aubrey Reynolds

Thank you, operator. Good morning, everyone, and welcome to GoodRx’s earnings conference call for the third quarter 2024. Joining me today are Scott Wagner, our Interim Chief Executive Officer; and Karsten Voermann, our Chief Financial Officer.

Before we begin, I’d like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding management’s plans, strategies, goals and objectives, our market opportunity, our anticipated financial performance, underlying trends in our business and industry, including ongoing changes in the pharmacy ecosystem, our value proposition, our long-term growth prospects, our direct and hybrid contracting approach, collaborations and partnerships with third parties, including our point-of-sale cash programs and our integrated savings program, our e-commerce strategy, and our capital allocation priorities. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties, and other important factors.

These factors including the factors discussed in the Risk Factor section of our Annual Report on Form 10-K for the year ended December 31st, 2023, and our other financial filings with the Securities and Exchange Commission could cause actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements made on this call. Any such forward-looking statements represents management’s estimates as of the date of this call, and we disclaim any obligation to update these statements even if subsequent events cause our views to change. In addition, we will be referencing certain non-GAAP metrics in today’s remarks. We have reconciled each non-GAAP metric to the nearest GAAP metric in the company’s earnings press release, which can be found in the overview page of our Investor Relations website at investors.goodrx.com. I’d also like to remind everyone that a replay of this call will become available there shortly as well.